THIS IS A DEVELOPMENT VERSION OF PROFILES. PLEASE GO TO THE PRODUCTION ENVIRONMENT FOR UPDATES

Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Robert Mannel and Joan Walker.
Robert Mannel
Connection Strength
2.846
Joan Walker
  1. Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study. J Clin Oncol. 2019 06 01; 37(16):1380-1390.
    View in: PubMed
    Score: 0.669
  2. Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer. N Engl J Med. 2019 11 14; 381(20):1929-1939.
    View in: PubMed
    Score: 0.174
  3. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2017 06; 18(6):779-791.
    View in: PubMed
    Score: 0.146
  4. Impact of histology and surgical approach on survival among women with early-stage, high-grade uterine cancer: An NRG Oncology/Gynecologic Oncology Group ancillary analysis. Gynecol Oncol. 2016 Dec; 143(3):460-465.
    View in: PubMed
    Score: 0.141
  5. Hypogastric artery aneurysm masquerading as an ovarian neoplasm. Gynecol Oncol. 1992 Dec; 47(3):382-4.
    View in: PubMed
    Score: 0.108
  6. A phase I study with an expanded cohort to assess feasibility of intravenous docetaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with previously untreated ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2012 Dec; 127(3):506-10.
    View in: PubMed
    Score: 0.106
  7. Recurrence and survival after random assignment to laparoscopy versus laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group LAP2 Study. J Clin Oncol. 2012 Mar 01; 30(7):695-700.
    View in: PubMed
    Score: 0.101
  8. A phase I study with an expanded cohort to assess the feasibility of intravenous paclitaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with untreated ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2012 Apr; 125(1):54-8.
    View in: PubMed
    Score: 0.101
  9. Phase II trial of intraperitoneal cisplatin combined with intravenous paclitaxel in patients with ovarian, primary peritoneal and fallopian tube cancer. Gynecol Oncol. 2011 Sep; 122(3):527-31.
    View in: PubMed
    Score: 0.097
  10. A phase I study with an expanded cohort to assess the feasibility of intraperitoneal carboplatin and intravenous paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: A Gynecologic Oncology Group study. Gynecol Oncol. 2011 May 01; 121(2):264-8.
    View in: PubMed
    Score: 0.095
  11. Laparoscopy compared with laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group Study LAP2. J Clin Oncol. 2009 Nov 10; 27(32):5331-6.
    View in: PubMed
    Score: 0.086
  12. Adjuvant chemotherapy for the "oldest old" ovarian cancer patients: can we anticipate toxicity-related treatment failure in a vulnerable population? Cancer. 2009 Apr 01; 115(7):1472-80.
    View in: PubMed
    Score: 0.083
  13. Ovarian cancer in the octogenarian: does the paradigm of aggressive cytoreductive surgery and chemotherapy still apply? Gynecol Oncol. 2008 Aug; 110(2):133-9.
    View in: PubMed
    Score: 0.079
  14. Carcinosarcoma of the ovary-a case series. Gynecol Oncol. 2006 Jan; 100(1):128-32.
    View in: PubMed
    Score: 0.065
  15. Phase I and Randomized Phase II Study of Ruxolitinib With Frontline Neoadjuvant Therapy in Advanced Ovarian Cancer: An NRG Oncology Group Study. J Clin Oncol. 2024 Jul 20; 42(21):2537-2545.
    View in: PubMed
    Score: 0.060
  16. Impact of individual physicians on enrollment of patients into clinical trials. Am J Clin Oncol. 2003 Apr; 26(2):171-3.
    View in: PubMed
    Score: 0.055
  17. Identification of Patients With Ovarian Cancer Experiencing the Highest Benefit From Bevacizumab in the First-Line Setting on the Basis of Their Tumor-Intrinsic Chemosensitivity (KELIM): The GOG-0218 Validation Study. J Clin Oncol. 2022 Dec 01; 40(34):3965-3974.
    View in: PubMed
    Score: 0.053
  18. A phase II trial of bevacizumab and rucaparib in recurrent carcinoma of the cervix or endometrium. Gynecol Oncol. 2022 07; 166(1):44-49.
    View in: PubMed
    Score: 0.052
  19. Laparoscopic pelvic and paraaortic lymph node dissection in the obese. Gynecol Oncol. 2002 Mar; 84(3):426-30.
    View in: PubMed
    Score: 0.051
  20. Surgical management of early-stage endometrial cancer in the elderly: is laparoscopy feasible? Gynecol Oncol. 2001 Dec; 83(3):563-8.
    View in: PubMed
    Score: 0.050
  21. Laparoscopic pelvic and paraaortic lymph node dissection: analysis of the first 100 cases. Gynecol Oncol. 2001 Sep; 82(3):498-503.
    View in: PubMed
    Score: 0.049
  22. Analysis of FIGO Stage IIIc endometrial cancer patients. Gynecol Oncol. 2001 May; 81(2):273-8.
    View in: PubMed
    Score: 0.048
  23. CT Perfusion as an Early Biomarker of Treatment Efficacy in Advanced Ovarian Cancer: An ACRIN and GOG Study. Clin Cancer Res. 2017 Jul 15; 23(14):3684-3691.
    View in: PubMed
    Score: 0.036
  24. Hepatic venoocclusive disease as a complication of whole abdominopelvic irradiation and treatment with the transjuglar intrahepatic portosystemic shunt: case report and literature review. Gynecol Oncol. 1996 May; 61(2):282-6.
    View in: PubMed
    Score: 0.034
  25. Use of ileocecal continent urinary reservoir in patients with previous pelvic irradiation. Gynecol Oncol. 1995 Dec; 59(3):376-8.
    View in: PubMed
    Score: 0.033
  26. Histologic effects of medroxyprogesterone acetate on endometrioid endometrial adenocarcinoma: a Gynecologic Oncology Group study. Int J Gynecol Pathol. 2014 Nov; 33(6):543-53.
    View in: PubMed
    Score: 0.031
  27. Cost analysis of Hickman catheter insertion at bedside in gynecologic oncology patients. J Am Coll Surg. 1994 Nov; 179(5):558-60.
    View in: PubMed
    Score: 0.031
  28. Phase II trial of vaginal cuff brachytherapy followed by chemotherapy in early stage endometrial cancer patients with high-intermediate risk factors. Gynecol Oncol. 2014 Jan; 132(1):50-4.
    View in: PubMed
    Score: 0.029
  29. Comparison of clinical versus surgical staging systems in vulvar cancer. Obstet Gynecol. 1992 Dec; 80(6):927-30.
    View in: PubMed
    Score: 0.027
  30. Do uterine risk factors or lymph node metastasis more significantly affect recurrence in patients with endometrioid adenocarcinoma? Gynecol Oncol. 2012 Apr; 125(1):94-8.
    View in: PubMed
    Score: 0.025
  31. Management of endometrial cancer with suspected cervical involvement. Obstet Gynecol. 1990 Jun; 75(6):1016-22.
    View in: PubMed
    Score: 0.023
  32. Preoperative predictors of positive margins after loop electrosurgical excisional procedure-Cone. Gynecol Oncol. 2006 Feb; 100(2):379-84.
    View in: PubMed
    Score: 0.017
  33. A comparison of stages IB1 and IB2 cervical cancers treated with radical hysterectomy. Is size the real difference? Gynecol Oncol. 2004 Oct; 95(1):70-6.
    View in: PubMed
    Score: 0.015
  34. Surgical-pathological predictors of disease-free survival and risk groupings for IB2 cervical cancer: do the traditional models still apply? Gynecol Oncol. 2004 Aug; 94(2):249-55.
    View in: PubMed
    Score: 0.015
  35. Outpatient implantation of a central venous access system in gynecologic oncology patients. J Reprod Med. 2003 Nov; 48(11):875-81.
    View in: PubMed
    Score: 0.014
  36. Method and timing of tumor volume measurement for outcome prediction in cervical cancer using magnetic resonance imaging. Int J Radiat Oncol Biol Phys. 2002 Jan 01; 52(1):14-22.
    View in: PubMed
    Score: 0.013
  37. Cost analysis of laparoscopy versus laparotomy for early endometrial cancer. Gynecol Oncol. 1999 Dec; 75(3):460-3.
    View in: PubMed
    Score: 0.011
  38. Epidermal growth factor receptor in vulvar malignancies and its relationship to metastasis and patient survival. Gynecol Oncol. 1997 Jun; 65(3):425-9.
    View in: PubMed
    Score: 0.009
  39. Incidence and location of para-aortic lymph node metastases in gynecologic malignancies. J Am Coll Surg. 1995 Jul; 181(1):72-4.
    View in: PubMed
    Score: 0.008
  40. Prognostic utility of epidermal growth factor receptor overexpression in endometrial adenocarcinoma. Cancer. 1994 Jan 15; 73(2):370-6.
    View in: PubMed
    Score: 0.007
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

THIS IS A DEVELOPMENT VERSION OF PROFILES. PLEASE GO TO THE PRODUCTION ENVIRONMENT FOR UPDATES